“Preclinical Formulation for the Pharmacokinetics and Efficacy of GBO-006, a Selective Polo Like Kinase 2 (PLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer”. ADMET and DMPK 4, no. 4 (December 26, 2016): 314–326. Accessed June 7, 2026. https://pub.iapchem.org/ojs/index.php/admet/article/view/341.